1. Scrip
  2. >>Therapy Areas

Long Wait Ahead For Novartis's Leqvio In US

German Launch In February, UK Maybe Q3

 
• By Kevin Grogan

The timeline for a US resubmission of the closely watched PCSK9-targeting cholesterol treatment could be either Q2 or Q3 and approval will depend on whether the FDA needs to make a physical inspection of an Italian facility.

delays
US patients won't be getting Leqvio any time soon • Source: Shutterstock

Any hopes for an imminent Europe-wide launch of Novartis AG's Leqvio or a speedy resolution of the issues that have held up US approval of the closely watched twice-yearly cholesterol drug have been cooled by CEO Vas Narasimhan.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapy Areas